Page 21 - Relapsing Remitting Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New study to examine the effects of MS disease-modifying therapy on cognitive fatigue Kessler Foundation researchers have received support from Genentech, a member of the Roche Group, to conduct an investigator-initiated study on the effects of ocrelizumab (Ocrevus) on cognitive fatigue in individuals with relapsing-remitting multiple sclerosis (MS). John DeLuca, PhD, senior vice president of Research and Training, is principal investigator for the study titled, A Biomarker for Cognitive Fatigue in MS using Functional Imaging . The study team includes Glenn Wylie, DPhil, director of the Rocco Ortenzio Neuroimaging Center at Kessler Foundation, Ekaterina Dobryakova, PhD, research scientist in the Center for Traumatic Brain Injury Research, and Helen Genova, PhD, assistant director of the Center for Neuropsychology and Neuroscience Research.

Helen genovaEkaterina dobryakovaGlenn wylieJohn delucaEmily hendersonRocco ortenzio neuroimaging center at kessler foundationKessler foundationRoche groupNeuroscience researchOrtenzio centerTraumatic brain injury researchCognitive fatigueRocco ortenzio neuroimaging centerMedical schoolMultiple sclerosisRelapsing remitting multiple sclerosis